STAGE IV LUNG CANCER AJCC V8

This early-phase trial is testing whether a personalized vaccine made from each patient's unique tumor proteins can safely boost the immune system against advanced breast cancer, melanoma, and lung cancer. The vaccine is given along with an immune-boosting drug (nivolumab) and an…

This study tests a special type of radiation called grid therapy, which delivers high doses to small parts of a tumor, combined with standard immunotherapy for people with stage IV non-small cell lung cancer that has stopped responding to treatment. About 20 adults will receive t…

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This early-stage trial is testing whether combining two drugs, carfilzomib and sotorasib, is safe for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will involve 15 participants and aims to find the best dose and wat…

This phase II trial is testing whether combining the chemotherapy drug temozolomide with the immunotherapy atezolizumab can help shrink tumors or slow the disease in people with advanced small cell lung cancer that has spread or returned. About 56 participants will receive the co…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if the combination is safe and helps the immune system fight cancer more effectively. Ab…

This early-phase trial tests whether adding low-dose interleukin-2 (IL-2) to the immunotherapy drug pembrolizumab (Keytruda) can better activate the immune system against stage IV non-small cell lung cancer. The study will enroll 15 people who have not had prior treatment for the…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This early-phase study tests a combination of two drugs, osimertinib and tegavivint, as the first treatment for people with a certain type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The main goal is to find the safest dose and see how well the drugs work togethe…

This study compares two types of radiation for people with small cell lung cancer that has spread to the brain. One method, stereotactic radiosurgery (SRS), targets only the tumors with a high dose of radiation. The other, hippocampal-avoidant whole brain radiotherapy (HA-WBRT) p…

This early-phase trial is testing whether the immunotherapy drug nivolumab can be safely given both into a vein and directly into the fluid around the spinal cord for people with melanoma or lung cancer that has spread to the lining of the brain. About 75 participants will receiv…

This phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune signals) with pembrolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has spread or returned. About 30 adults whose tumors have a specific PD-L1…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This early-stage trial tests a new drug called MRX-2843 combined with the standard targeted therapy osimertinib in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see if the combination can stop tumor growth by blocking key enz…

This phase II trial tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control advanced non-small cell lung cancer when immunotherapy alone starts to show signs of failing. About 20 adults whose cancer has progressed while on standard immunotherapy d…

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with advanced non-small cell lung cancer that has a specific MET gene mutation. About 56 participants will be randomly assigned to one of two treatment groups. The goal is to see…

This study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …

This study tests a new drug combination (GT103 plus pembrolizumab) for people with advanced or spreading non-small cell lung cancer that has a specific gene change called STK11. The goal is to see if the combo can shrink tumors or slow the cancer better than current options. Abou…

This study tests whether adding two types of focused radiation (BgRT and SBRT) to the standard pill osimertinib can better control EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with stage IV non-small cell lung cancer will receive the comb…

This study tests a type of radiation therapy (craniospinal irradiation) for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this treatment can help control the disease and improve quality of life. A…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This early-stage trial tests the safety and best dose of two drugs—vismodegib and atezolizumab—given together to people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab boosts the imm…

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in people with a specific type of advanced lung cancer (LKB1-mutant adenocarcinoma) that has stopped responding to standard treatment. The goal is to see if this t…

This early-phase trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose cancer has stopped responding to other treatments. The main goals are to find the safest dose and understand side effects. Res…

This early-stage trial tests a new drug (PBF-1129) combined with an immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Participants must have already tr…

This study tests if a precise type of proton radiation (pCSI) can help people with breast or lung cancer that has spread to the fluid-filled space around the brain and spinal cord live longer than standard x-ray radiation. About 115 participants will receive either pCSI or standa…

This study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. The trial enrolls 304 participants with stage IIIB-IV cancer and a specific PD-L1 level. Th…

This study is for people with stage IV or returning non-small cell lung cancer who have already had chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) to the same two drugs plus a third drug called cemiplimab. The goal is to see i…

This study tests a special dye that attaches to lung cancer cells and makes them glow under a camera during surgery. The goal is to help surgeons see and remove all cancer tissue more accurately. About 30 adults with lung cancer or lung metastases will receive the dye before thei…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, as well as for their family caregivers. About 400 patient-caregiver pairs will take part…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…

This study tests whether giving radiation in three smaller doses (fractionated stereotactic radiosurgery) is better than the usual single large dose for people whose cancer has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be ran…

This study tests whether a new screening tool can help people with advanced lung cancer better understand their illness and treatment goals. About 100 patients will either use the tool or receive usual care. The goal is to see if the tool leads to more informed decisions that mat…

This study tests a communication tool that helps doctors and patients with non-small cell lung cancer work together on treatment decisions. About 100 patients and their doctors will use the tool during appointments to see if it improves how decisions are made and how satisfied pa…

This study looks at how often people with metastatic non-small cell lung cancer have trouble sleeping. Researchers will use a simple questionnaire to measure insomnia severity. The goal is to understand how common this problem is in this group, not to test a new treatment. About …

This study is observing 800 people with advanced lung, colorectal, or pancreatic cancer to understand why some lose weight and muscle (cachexia). Researchers hope to find distinct subtypes of cachexia, which could lead to better, more personalized treatments in the future. Partic…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation for stage IV non-small cell lung cancer. Researchers want to see if these scans can help predict how well the cancer responds to treatment. About 80 adults with advanced lung cancer who haven't ha…

This early study tests if a portable device that creates electric fields is safe and practical for people with breast or lung cancer that has spread to the lining of the spine. Only 5 participants will wear the device for at least 28 days. The goal is to see if the treatment is t…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…

This study looks at blood and tissue samples from people with advanced non-small cell lung cancer to find markers that predict how well immunotherapy works. The goal is to use these markers to choose the best second-line treatment if the first one stops working. About 535 partici…